ADMINISTRATION OF ERYTHROPOIETIN IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION: GOOD OR NOT?. (8th October 2012)

• Record Type: Journal Article
• Authors: Mingqiang, Fu; Juying, Qian; Jingmin, Zhou; Chunyu, Zhang; Hongying, Liu; Jianfeng, Xu; Yunzeng, Zou; Junbo, Ge; Junbo, Ge
• Is Part Of: Heart. Volume 98(2012)Supplement 2
• Page Start: E173
• Page End: E173
• Publication Date: 2012-10-08
• Subjects: Heart -- Diseases -- Treatment -- Periodicals; Cardiology -- Periodicals; 616.12
• DOI: 10.1136/heartjnl-2012-302920j.40
• Languages: English
• ISSNs: 1355-6037

Abstract

Abstract : Objectives: To assess the effects of intravenous erythropoietin (EPO) administration in patients with acute myocardial infarction (AMI). Methods: We searched MEDLINE, EMBASE, and the Cochrane database through June 2011. Eligible studies were randomised controlled trials of intravenous EPO administration in AMI patients with follow-up duration equal to or longer than 1 month. Results: A total of 10 trials involving 1270 participants were identified. Over a weighted mean (SD) follow-up of 3.27 (0.25) months, standard medical care together with EPO significantly reduced infarct size (SMD −0.35, 95% CI −0.68 to −0.02; p=0.04) and left ventricular end-systolic volume (LVESV) (SMD −0.59, 95% CI −1.04 to −0.14; p=0.009) while improved left ventricular ejection fraction (LVEF) (SMD 1.47, 95% CI: 0.51 to 2.42; p=0.003). And EPO administration did not add death, reinfarction, stroke and thrombosis events. Meta-regression showed a statistically significant association between infarct size decrement and age and follow-up duration (both p<0.001). Conclusions: EPO administration in acute MI patients was safe and effective.